Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

被引:11
作者
Tsai, Yi-Giien [1 ,2 ,3 ,4 ]
Liao, Pei-Fen [3 ,5 ]
Hsiao, Kai-Hung [6 ]
Wu, Hung-Ming [7 ]
Lin, Ching-Yuang [8 ]
Yang, Kuender D. [9 ,10 ]
机构
[1] Changhua Christian Childrens Hosp, Dept Pediat, Changhua, Taiwan
[2] Kaohsiung Med Univ, Sch Med, Kaohsiung 807, Kaohsiung, Taiwan
[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[4] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan
[5] Chung Shan Med Univ Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Taichung, Taiwan
[6] Changhua Christian Hosp, Dept Allergy Immunol & Rheumatol, Changhua, Taiwan
[7] Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan
[8] China Med Univ Hosp, Childrens Hosp, Div Pediat Nephrol, Taichung, Taiwan
[9] MacKay Mem Hosp, Dept Pathol, New Taipei City, Taiwan
[10] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
systemic lupus erythematosus; lupus nephritis; regulatory T cells; interleukin-2; B regulatory cells; LOW-DOSE IL-2; B-CELLS; DISEASE-ACTIVITY; CD4(+); ACTIVATION; FOXP3; DIFFERENTIATION; SUPPRESSION; ASSOCIATION; CAPACITY;
D O I
10.3389/fimmu.2023.1230264
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus
    Shao Miao
    Sun XiaoLin
    Sun He
    He Jing
    Zhang RuiJun
    Zhang Xia
    Li ZhanGuo
    [J]. 中华医学杂志英文版, 2018, 131 (13) : 1520 - 1526
  • [42] Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus
    Shao, Miao
    Sun, Xiao-Lin
    Sun, He
    He, Jing
    Zhang, Rui-Jun
    Zhang, Xia
    Li, Zhan-Guo
    [J]. CHINESE MEDICAL JOURNAL, 2018, 131 (13) : 1520 - 1526
  • [43] Interleukin-2 receptor gene polymorphism in Chinese patients with systemic lupus erythematosus
    Tsai, Chang-Hai
    Huang, Chung-Ming
    Lo, Sui-Foon
    Wan, Lei
    Tsai, Fuu-Jen
    [J]. RHEUMATOLOGY INTERNATIONAL, 2006, 26 (10) : 949 - 950
  • [44] Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy
    Lo, Mindy S.
    Tsokos, George C.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2018, 30 (02) : 222 - 228
  • [45] Aberrant T cell subsets and cytokines expression profile in systemic lupus erythematosus
    Haiyan Zhou
    Bailong Hu
    Niwen Huang
    Xiangang Mo
    Wei Li
    Bei Zhang
    Bo Wei
    Mingzhu Gao
    Yiming Wang
    Xingde Liu
    Joshua Liao
    [J]. Clinical Rheumatology, 2018, 37 : 2405 - 2413
  • [46] Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
    Dai, Xiaofeng
    Fan, Yuting
    Zhao, Xing
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [47] Interleukin 2 and systemic lupus erythematosus Beyond the transcriptional regulatory net abnormalities
    Gomez-Martin, Diana
    Diaz-Zamudio, Mariana
    Crispin, Jose Carlos
    Alcocer-Varela, Jorge
    [J]. AUTOIMMUNITY REVIEWS, 2009, 9 (01) : 34 - 39
  • [48] Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics
    Raeber, Miro E.
    Caspar, Dominic P.
    Zurbuchen, Yves
    Guo, Nannan
    Schmid, Jonas
    Michler, Jan
    Martin, Alina C.
    Steiner, Urs C.
    Moor, Andreas E.
    Koning, Frits
    Boyman, Onur
    [J]. IMMUNITY, 2024, 57 (09) : 2232 - 2250.e10
  • [49] CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview
    Abdalhadi, Haneen M.
    Chatham, Walter W.
    Alduraibi, Fatima K.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (19)
  • [50] Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis
    Mistry, Pragnesh
    Kaplan, Mariana J.
    [J]. CLINICAL IMMUNOLOGY, 2017, 185 : 59 - 73